Search Result
Results for "
IMC
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P9905
-
|
C225; IMC-C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
-
- HY-P9964
-
|
11F8; IMC-11F8; LY3012211
|
EGFR
|
Cancer
|
|
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
|
-
-
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
-
-
- HY-P99364
-
|
Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1
|
VEGFR
Apoptosis
p38 MAPK
Akt
|
Endocrinology
Cancer
|
|
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .
|
-
-
- HY-P990717
-
|
IMC-F106C
|
CD3
|
Cancer
|
|
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3 + T cells to kill PRAME + tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer .
|
-
-
- HY-P99189
-
|
IMC-A12; NSC742460
|
IGF-1R
|
Cancer
|
|
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
|
-
-
- HY-P99375
-
|
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)
|
Tyrosinase
c-Met/HGFR
|
Cancer
|
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
|
-
-
- HY-P990608
-
|
IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)
|
CD3
|
Inflammation/Immunology
|
|
Alpitatug (IMC 3C5) is a CHO-expressed human antibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P991106
-
|
LY-3076226 antibody
|
FGFR
|
Cancer
|
|
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P99622
-
|
IMC-20D7S
|
Tyrosinase
|
Cancer
|
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
|
-
-
- HY-176202
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC (compound LIV1-IMC (12) linker-payload) is a linker-payload conjugate, used in the synthesis of antibody-drug conjugates (ADCs).TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC contains TLR7/8 agonist (HY-170770) (ADC payload) and a linker (HY-176478) .
|
-
-
- HY-P990014
-
|
IMC-001; STI-3031
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
|
-
-
- HY-P991641
-
|
LY3012218
|
FLT3
p38 MAPK
STAT
PI3K
Akt
|
Cancer
|
|
IMC-EB10 (LY3012218) is an anti-FLT3 monoclonal antibody. IMC-EB10 binds to FLT3 with high affinity (Kd = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC50 ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research .
|
-
-
- HY-169596
-
|
|
Aminopeptidase
|
Cancer
|
|
Arphamenine A is an aminopeptidase B inhibitor found in Chromobacteriuin violaceum HMG361-CF4. Arphamenine A can inhibit the activity of aminopeptidase B, and can inhibit sarcoma 180 and invasive micropapillary carcinoma (IMC) cancer .
|
-
-
- HY-N14144
-
|
|
Bacterial
|
Infection
Cancer
|
|
Cremimycin has anti-Gram-positive bacteria activity including methicillin-resistant Staphylococcus aureus (MRSA), MIC is 0.2-0.39 μg/mL. Cremimycin shows cytotoxicity to mouse tumor cell lines P388, L1210, IMC, S180, B16 and SS3 in vitro .
|
-
-
- HY-19606
-
|
Antibiotic MI 43-37F11
|
Interleukin Related
NO Synthase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Cytogenin (Antibiotic MI 43-37F11) is an orally active antineoplastic antibiotic. Cytogenin regulates the inflammatory cytokine, reduces the levels of iNOS, NO and IL-6 in mouse macrophages, and exhibits antidiabetic efficacy in mice. Cytogenin inhibits growth of Ehrlich ascites tumor in mouse model .
|
-
-
- HY-N14139
-
|
|
Bacterial
|
Infection
Cancer
|
|
Dioxamycin has anti-Gram-positive bacterial activity. Dioxamycin can inhibit Staphylococcus aureus 209P with a MIC of 3.12 μg/mL. Dioxamycin inhibits the growth of L1210, P388, IMC, LX-1 and SC-6 cells with IC50s (μg/mL) of 2.7, 1.4, 6.0, 2.0 and 2.5, respectively .
|
-
-
- HY-N10653
-
|
(-)-Altemicidin
|
Others
|
Cancer
|
|
Altemicidin is a monoterpene alkaloid originally isolated from S. sioyaensis with acaricidal and anticancer activities. It is acaricidal to two-spotted spider mites (T. urticae) in a greenhouse pot test at concentrations of 10 and 100 ppm. Altemicidin inhibits the growth of murine L1210 lymphocytic leukemia and IMC carcinoma cells (IC50s=0.84 and 0.82 μg/mL, respectively). It is toxic to mice with an LD50 value of 0.3 mg/kg.
|
-
-
- HY-121365
-
|
|
Bacterial
|
Infection
|
|
Forphenicinol is an immunomodulator and a derivative of the bacterial metabolite forphenicine. It increases the phagocytosis of yeast by peritoneal macrophages isolated from thioglycolate-stimulated mice. Forphenicinol (100 μg/animal) prevents cyclophosphamide-induced suppression of delayed-type hypersensitivity (DTH), as well as enhances DTH in response to the hapten oxazolone or sheep red blood cells in mice. It enhances the bactericidal activity of macrophages against P. aeruginosa in mice when administered at a dose of 0.5 mg/kg.2 Forphenicinol (15.6-1,000 μg/animal) increases survival in a mouse model of P. aeruginosa infection. It also inhibits tumor growth in S180 sarcoma and IMC carcinoma mouse xenograft models when administered at doses ranging from 0.05 to 5 mg/kg per day.
|
-
-
- HY-106026
-
|
IMC-XV
|
Antibiotic
Bacterial
|
Infection
|
|
YM 133 (IMC-XV) is a semisynthetic macrolide antibiotic with potent bactericidal activity. YM 133 shows activity against Erythromycin (HY-B0220)-, Josamycin (HY-B1920)-, and rokitamycin-resistant (MIC ≥ 100 μg/mL) strains of staphylococci, streptococci, Bacteroides spp., and Clostridium spp. YM 133 exhibits excellent activity against macrolide-resistant strains and against anaerobes. YM 133 can be used for antibacterial research .
|
-
-
- HY-N14530
-
|
|
Bacterial
|
Infection
Cancer
|
|
Cremeomycin has anti-Gram-positive bacteria activity including methicillin-resistant Staphylococcus aureus (MRSA), MIC is 0.2-0.39 μg/mL. Cremeomycin shows cytotoxicity to mouse tumor cell lines P388, L1210, IMC, S180, B16 and SS3 in vitro .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P9905
-
|
C225; IMC-C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
(5)
-
- HY-P9964
-
|
11F8; IMC-11F8; LY3012211
|
EGFR
|
Cancer
|
|
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
|
-
(5)
-
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
-
(5)
-
- HY-P99364
-
|
Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1
|
VEGFR
Apoptosis
p38 MAPK
Akt
|
Endocrinology
Cancer
|
|
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .
|
-
(5)
-
- HY-P990717
-
|
IMC-F106C
|
CD3
|
Cancer
|
|
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3 + T cells to kill PRAME + tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer .
|
-
(5)
-
- HY-P99189
-
|
IMC-A12; NSC742460
|
IGF-1R
|
Cancer
|
|
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
|
-
(5)
-
- HY-P99375
-
|
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)
|
Tyrosinase
c-Met/HGFR
|
Cancer
|
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
|
-
(5)
-
- HY-P990608
-
|
IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)
|
CD3
|
Inflammation/Immunology
|
|
Alpitatug (IMC 3C5) is a CHO-expressed human antibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-P991106
-
|
LY-3076226 antibody
|
FGFR
|
Cancer
|
|
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
-
- HY-P990621
-
|
IMC-TR1
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
LY3022859 (IMC-TR1) is a CHO-expressed human antibody that targets TBFbR2. LY3022859 (IMC-TR1) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 143 kDa. The isotype control for LY3022859 (IMC-TR1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-P99622
-
|
IMC-20D7S
|
Tyrosinase
|
Cancer
|
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
|
-
(5)
-
- HY-P990619
-
|
IMC-CS4
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
LY3022855 is a CHO-expressed human antibody that targets CSF1R/M-CSFR/CD115. LY3022855 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LY3022855 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-P990489
-
|
IMC-2C5
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-PDGFRB/CD140b Antibody (IMC-2C5) is a humanized antibody expressed in CHO cells that targets PDGFRB/CD140b. Anti-PDGFRB/CD140b Antibody (IMC-2C5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.54 kDa. The isotype control for Anti-PDGFRB/CD140b Antibody (IMC-2C5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-P990014
-
|
IMC-001; STI-3031
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
|
-
(5)
-
- HY-P991641
-
|
LY3012218
|
FLT3
p38 MAPK
STAT
PI3K
Akt
|
Cancer
|
|
IMC-EB10 (LY3012218) is an anti-FLT3 monoclonal antibody. IMC-EB10 binds to FLT3 with high affinity (Kd = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC50 ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research .
|
-
(5)
-
- HY-P990603
-
|
RG-6290
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
IMC-C103C is a human antibody expressed in CHO cells, targeting MAGE-A4. IMC-C103C contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for IMC-C103C can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
